IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about General Updates
IOLCP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
IOL Chemicals and Pharmaceuticals has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & Health Care (EDQM) for its API product 'Clopidogrel Besilate' on 23rd February 2026. This is in addition to the existing CEP already held by the company for 'Clopidogrel Bisulphate.' Clopidogrel is an antiplatelet drug widely used for treating and preventing cardiovascular diseases. The CEP certification enables the company to supply this API to European pharmaceutical markets.
This regulatory approval strengthens IOLCP's presence in the European API market and expands its cardiovascular product portfolio, which is positive for future export revenues. It signals compliance with stringent European quality standards, potentially boosting investor confidence.